Plots by hemophilia subtype of (A) concizumab plasma concentration (geometric mean) vs time; (B) free TFPI plasma concentration (mean) vs time; (C) prothrombin fragments 1 + 2 vs concizumab plasma concentration; and (D) D-dimers vs concizumab plasma concentration in the main + extension parts of the phase 2 concizumab trials explorer4 (HAwI, HBwI) and explorer5 (HA). All data from visit 16 were allocated to 118 weeks (HAwI and HBwI) or 126 weeks (HA) after first concizumab dose (panels A and B). Data below the lower limit of quantification (LLOQ) were included as LLOQ/2 in the calculations. Horizontal dashed lines in panel A indicate a concizumab exposure level between 200 and 4000 ng/mL. Baseline values for panels C and D were assigned to Visit 9 (last treatment during main part) for the on-demand treatment arm in explorer4. BC, baseline concizumab; FEU, fibrinogen-equivalent units; LLN, lower limit of normal; ULN, upper limit of normal.